Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Solriamfetol Hydrochloride Patent Expiration

Solriamfetol Hydrochloride is Used for improving wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea through a dosing regimen that includes oral administration of Solriamfetol. It was first introduced by Axsome Malta Ltd in its drug Sunosi on Jun 17, 2019.


Solriamfetol Hydrochloride Patents

Given below is the list of patents protecting Solriamfetol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sunosi US10195151 Formulations of (R)-2-amino-3-phenylpropyl carbamate Sep 05, 2037 Axsome Malta
Sunosi US10351517 Treatment of sleep-wake disorders Jun 07, 2026 Axsome Malta
Sunosi US10512609 Formulations of (R)-2-amino-3-phenylpropyl carbamate Sep 05, 2037 Axsome Malta
Sunosi US10912754 Methods and compositions for treating excessive sleepiness Jun 01, 2038 Axsome Malta
Sunosi US10940133 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US10959976 Methods and compositions for treating excessive sleepiness Jun 01, 2038 Axsome Malta
Sunosi US11160779 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11439597 Formulations of (R)-2-amino-3-phenylpropyl carbamate Sep 05, 2037 Axsome Malta
Sunosi US11560354 Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof Mar 06, 2039 Axsome Malta
Sunosi US11648232 Methods and compositions for treating excessive sleepiness Jun 01, 2038 Axsome Malta
Sunosi US11753368 Treatment of sleep-wake disorders Jun 07, 2026 Axsome Malta
Sunosi US11771666 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US11771667 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US11779554 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US11793776 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US11839598 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11839599 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11850226 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11850227 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11850228 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11857528 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11865098 Methods and compositions for treating excessive sleepiness Jun 01, 2038 Axsome Malta
Sunosi US11872203 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US11872204 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US11969404 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11986454 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11986455 Methods of providing solriamfetol therapy to subjects with impaired renal function Mar 19, 2040 Axsome Malta
Sunosi US11998639 Formulations of (R)-2-amino-3-phenylpropyl carbamate Sep 05, 2037 Axsome Malta
Sunosi US12005036 Methods of administering solriamfetol to lactating women Dec 30, 2042 Axsome Malta
Sunosi US8440715 Treatment of sleep-wake disorders Jun 11, 2031 Axsome Malta
Sunosi US8877806 Treatment of sleep-wake disorders Jun 07, 2026 Axsome Malta
Sunosi US9604917 Treatment of sleep-wake disorders Jun 07, 2026 Axsome Malta


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Solriamfetol Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Solriamfetol Hydrochloride.

Event Date Patent/Publication
Patent litigations
Mail Patent eCofC Notification 28 May, 2024 US11969404
Recordation of Patent eCertificate of Correction 28 May, 2024 US11969404
Patent eCofC Notification 28 May, 2024 US11969404
Email Notification 28 May, 2024 US11969404
Mail Patent eCofC Notification 21 May, 2024 US11771667
Recordation of Patent eCertificate of Correction 21 May, 2024 US11771667
Email Notification 21 May, 2024 US11771667
Patent eCofC Notification 21 May, 2024 US11771667
Change in Power of Attorney (May Include Associate POA) 03 May, 2024 US8877806
Email Notification 03 May, 2024 US8877806



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳